Review ArticlesManagement of Anticoagulation and Antiplatelet Therapy in Glaucoma SurgeryShukla, Aakriti G. MD*; Ramulu, Pradeep Y. MD PhD†Author Information *Wills Eye Hospital, Thomas Jefferson University, Philadelphia, PA †Wilmer Eye Institute, Johns Hopkins University, Baltimore, MD P.Y.R.: NIH – Grant support; Ivantis Inc. – Consulting; W. L. Gore – Consulting; Aerie Pharmaceuticals – Consulting; Thea Pharmaceutical – Lecture fees. Disclosure: The authors declare no conflict of interest. Reprints: Aakriti G. Shukla, MD, Wills Eye Hospital, 840 Walnut Street, Suite 1110, Philadelphia, PA 19107 (e-mail: firstname.lastname@example.org). Journal of Glaucoma: September 2020 - Volume 29 - Issue 9 - p 732-741 doi: 10.1097/IJG.0000000000001594 Buy SDC Metrics Abstract The use of antithrombotic therapy is rising as the population of older adults grows and novel agents with wider indications emerge. Likewise, surgical treatment of glaucoma may become increasingly common as the prevalence of glaucoma increases and innovative treatment options are developed. These trends highlight the need to understand how best to manage antithrombotic therapy in the context of glaucoma surgery. This review article describes current literature on antithrombotic therapy and perioperative thromboembolic risk evaluation based on individual factors. In addition, guidance is offered on the management of antithrombotic therapy in the setting of each type of glaucoma surgery, with an emphasis on a multidisciplinary approach involving the patients’ treating physicians. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.